R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Articles

Perspectives on Treating CCA Moving Forward

May 3rd 2021

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

Immunotherapy for Advanced Cholangiocarcinoma

May 3rd 2021

The role of MSI testing and potential use of immunotherapy to treat patients with advanced cholangiocarcinoma.

Implications for Using FGFR Inhibitors in Advanced CCA

April 19th 2021

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events

April 19th 2021

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

FGFR Inhibitors for Advanced Cholangiocarcinoma

April 12th 2021

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Promoting the Importance of Molecular Testing in CCA

April 12th 2021

The value of early molecular testing in cholangiocarcinoma and importance of promoting its role to both patients and GI oncologists.

Advanced Cholangiocarcinoma: Molecular Testing

April 5th 2021

Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.

Advanced Cholangiocarcinoma: Transition to Precision Medicine

April 5th 2021

A panel of GI oncologists comment on the transition to targeted therapy and immunotherapy as treatments for advanced cholangiocarcinoma, as well as highlight predictive and prognostic markers that can help guide treatment decisions with novel therapies.

Treating Unresectable, Advanced Cholangiocarcinoma

March 29th 2021

Treatment recommendations, including supportive care options and the role of liver-directed therapy for patients with an unresectable, advanced bile duct cancer.

Neoadjuvant Therapy for Advanced Cholangiocarcinoma

March 29th 2021

An overview of potential options, as well as trials, further exploring neoadjuvant approaches for the management of patients with advanced cholangiocarcinoma.

Optimizing Adjuvant Therapy for Advanced Cholangiocarcinoma

March 22nd 2021

Insight regarding best timing to initiate an appropriate adjuvant therapy in patients with advanced cholangiocarcinoma, and the role of ctDNA analysis in the postsurgical setting.

Adjuvant Therapy for Advanced Cholangiocarcinoma

March 22nd 2021

Current treatment approaches for advanced cholangiocarcinoma, despite current gaps that can be considered in the adjuvant setting, as highlighted by GI oncologists.

Liver Transplantation for Advanced Cholangiocarcinoma

March 15th 2021

Scenarios for which liver transplantation may be appropriate in advanced cholangiocarcinoma.

Advanced Cholangiocarcinoma: Criteria for Resection

March 15th 2021

Panelists discuss types of scans and other testing results that can be used to help identify patients with an advanced bile duct cancer who are eligible for surgical resection.

Advanced Cholangiocarcinoma: Current Patient Prognosis

March 8th 2021

GI oncologists react to a prognosis for patients with newly diagnosed advanced cholangiocarcinoma and discuss how they counsel patients on goals of care and treatment expectations.

Cholangiocarcinoma: Importance of Adequate Tissue Collection

March 8th 2021

Best practices for working with other colleagues to ensure adequate tissue collection occurs when conducting a biopsy on a patient suspected of having cholangiocarcinoma, as well as considerations for next-generation sequencing.

Cholangiocarcinoma: Appropriate Diagnostic Work-Up

March 1st 2021

Types of assessments that are used to help appropriately work up a patient suspected of having a bile duct cancer.

Rising Incidence of Cholangiocarcinoma

March 1st 2021

Factors that may contribute to the rise in the number of cholangiocarcinoma cases being reported, as suggested by GI oncologists.

Heterogeneous Nature of Cholangiocarcinoma

February 22nd 2021

GI oncologists explain the complicated nature of cholangiocarcinoma as it relates to the disease’s underlying pathogenesis.

Cholangiocarcinoma Described

February 22nd 2021

Dr Sameek Roychowdhury, of the James Cancer Hospital Solove Research Institute, describes what cholangiocarcinoma is, specifically highlighting how the disease often presents in patients.